Fatty acid acetylated salicylates and their uses
AssigneeCatabasis Pharmaceuticals, Inc.
InventorsJill C. Milne, Michael R. Jirousek, Jean E. Bemis, Jesse J. Smith
Life of this patent
Estimating the term…
Abstract
The invention relates to Fatty Acid Acetylated Salicylate Derivatives; compositions comprising an effective amount of a Fatty Acid Acetylated Salicylate Derivative; and methods for treating or preventing an inflammatory disorder comprising the administration of an effective amount of a Fatty Acid Acetylated Salicylate Derivative.
Claims22
A method of treating inflammation that is associated with a metabolic disorder, wherein the metabolic disorder is selected from the group consisting of cardiovascular disease, arrhythmia, coronary artery disease, and hypertriglyceridimia, comprising administering to a patient in need thereof an effective amount of a compound of Formula I:
- or a pharmaceutically acceptable salt, enantiomer, or stereoisomer thereof, wherein:
- R1, R2, R3, and R4 are each independently selected from the group consisting of H, Cl, F, CN, —NH(C1-C3 alkyl), —N(C1-C3 alkyl)2, —NH(C(O)C1-C3 alkyl), —N(C(O)C1-C3 alkyl)2, —C(O)H, —C(O)C1-C3 alkyl, —C(O)OC1-C3 alkyl, —C(O)NH2, —C(O)NH(C1-C3 alkyl), —C(O)N(C1-C3 alkyl)2, —O—C1-C3 alkyl;
- W1 is NH and W2 is selected from null, O, or NH;
- - - - - - represents an optional bond that when present requires that Q is null;
- a and c are each independently H, CH3, —OCH3, —OCH2CH3, or C(O)OH;
- b is H, CH3, C(O)OH, or O—Z;
- d is H or C(O)OH;
- each n, o, p, and q is independently 0 or 1;
- each Z is H or
- with the proviso that there is at least one
- in the compound;
- each r is independently 2 or 3;
- each s is independently 5 or 6;
- each t is independently 0 or 1;
- Q is null, C(O)CH3, Z,
- e is H or any one of the side chains of the naturally occurring amino acids;
- W3 is null, O, or —N(R)—;
- R is H or C1-C3 alkyl;
- and
- T is H, C(O)CH3, or Z.
A method of treating inflammation that is associated with a neurodegenerative disorder selected from the group consisting of Huntington's Disease, infectious meningitis, encephalomyelitis, Parkinson's disease, and encephalitis, comprising administering to a patient in need thereof an effective amount of a compound of Formula I:
- or a pharmaceutically acceptable salt, enantiomer, or stereoisomer thereof,
- wherein:
- R1, R2, R3, and R4 are each independently selected from the group consisting of H, Cl, F, CN, —NH(C1-C3 alkyl), —N(C1-C3 alkyl)2, —NH(C(O)C1-C3 alkyl), —N(C(O)C1-C3 alkyl)2, —C(O)H, —C(O)C1-C3 alkyl, —C(O)OC1-C3 alkyl, —C(O)NH2, —C(O)NH(C1-C3 alkyl), —C(O)N(C1-C3 alkyl)2, —O—C1-C3 alkyl:
- W1 is NH and W2 is selected from null, O, or NH;
- - - - - - represents an optional bond that when present requires that Q is null;
- a and c are each independently H, CH3, —OCH3, —OCH2CH3, or C(O)OH;
- b is H, CH3, C(O)OH, or O—Z;
- d is H or C(O)OH;
- each n, o, p, and q is independently 0 or 1;
- each Z is H or
- with the proviso that there is at least one
- in the compound;
- each r is independently 2 or 3;
- each s is independently 5 or 6;
- each t is independently 0 or 1;
- Q is null, C(0)CH3, Z,
- e is H or any one of the side chains of the naturally occurring amino acids;
- W3 is null, O, or —N(R)—;
- R is H or C1-C3 alkyl;
- and
- T is H, C(O)CH3, or Z.
(canceled)
A method of treating inflammation that is associated with a muscle wasting disorder selected from the group consisting of dermatomyositis, inclusion body myositis, polymyositis, and cachexia, comprising administering to a patient in need thereof an effective amount of a compound of Formula I:
- or a pharmaceutically acceptable salt, enantiomer, or stereoisomer thereof,
- wherein:
- R1, R2, R3, and R4 are each independently selected from the group consisting of H, Cl, F, CN, —NH(C1-C3 alkyl), —N(C1-C3 alkyl)2, —NH(C(O)C1-C3 alkyl), —N(C(O)C1-C3 alkyl)2, —C(O)H, —C(O)C1-C3 alkyl, —C(O)OC1-C3 alkyl, —C(O)NH2, —C(O)NH(C1-C3 alkyl), —C(O)N(C1-C3 alkyl)2, —O—C1-C3 alkyl;
- W1 is NH and W2 is selected from null, O, or NH;
- - - - - - represents an optional bond that when present requires that Q is null;
- a and c are each independently H, CH3, —OCH3, —OCH2CH3, or C(O)OH;
- b is H, CH3, C(O)OH, or O—Z;
- d is H or C(O)OH;
- each n, o, p, and q is independently 0 or 1;
- each Z is H or
- with the proviso that there is at least one
- in the compound;
- each r is independently 2 or 3;
- each s is independently 5 or 6;
- each t is independently 0 or 1;
- Q is null, C(O)CH3, Z,
- e is H or any one of the side chains of the naturally occurring amino acids;
- W3 is null, O, or —N(R)—;
- R is H or C1-C3 alkyl;
- and
- T is H, C(O)CH3, or Z.
22-30. (canceled)
Dependencies are inferred from the claim text.